会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明申请
    • FUSED HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES
    • 融合的杂环衍生物,包含衍生物的药物组合物,以及用于医疗用途的组合物的用途
    • US20100081674A1
    • 2010-04-01
    • US12595931
    • 2008-04-16
    • Kohsuke OhnoNoboru Kamada
    • Kohsuke OhnoNoboru Kamada
    • A61K31/519C07D495/04
    • C07D495/04
    • The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides fused heterocyclic derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A is 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; RA is halogen, alkyl, alkenyl, alkynyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl, etc.; ring B is aryl or heteroaryl; RB is halogen, alkyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl, etc.; E1 and E2 are oxygen atom, etc.; Q is hydrogen atom, alkyl, alkylsulfonyl, acyl, etc.; X is -(alkylene)-Z, —CO—Y, —SO2—Y, etc. (in which Y is Z or amino, etc.; Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.
    • 本发明提供了可用作预防或治疗性激素依赖性疾病等的试剂的化合物。 也就是说,本发明提供具有GnRH拮抗活性的由以下通式(I)表示的稠合杂环衍生物,含有它们的药物组合物,其药用用途等。 在式(I)中,环A是5元环状不饱和烃或5元杂芳基; RA是卤素,烷基,烯基,炔基,羧基,烷氧基,氨基甲酰基,烷基氨基甲酰基等; 环B是芳基或杂芳基; RB是卤素,烷基,羧基,烷氧基,氨基甲酰基,烷基氨基甲酰基等; E1和E2是氧原子等; Q是氢原子,烷基,烷基磺酰基,酰基等; X是 - (亚烷基)-Z,-CO-Y,-SO2-Y等(其中Y是Z或氨基等; Z是环烷基,杂环烷基,芳基,杂芳基等)
    • 24. 发明申请
    • PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME
    • 吡唑衍生物,含有该药物的药物组合物,在其生产中的药物用途及其中间体
    • US20100029919A1
    • 2010-02-04
    • US12534452
    • 2009-08-03
    • Hideki FujikuraNorihiko KikuchiShigeki TazawaTokuhisa YamatoMasayuki Isaji
    • Hideki FujikuraNorihiko KikuchiShigeki TazawaTokuhisa YamatoMasayuki Isaji
    • C07H17/02
    • C07D405/04A61K31/7056C07D231/20C07D401/04C07D409/04C07H17/02Y10S514/866
    • The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group selected from the following groups: , and the other represents —(CH2)n—Ar wherein Ar represents an optionally substituted C6-10 aryl group or an optionally substituted C1-9 heteroaryl group; and n represents an integral number from 0 to 2, an optionally substituted C1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C2-9 heterocycloalkyl group or an optionally substituted heterocycle-fused phenyl group; R represents an optionally substituted C3-8 cycloalkyl group, an optionally substituted C6-10 aryl group etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human 1,5-anhydroglucitol/fructose/mannose transporter and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose or a disease associated with hyperglycemia (e.g., diabetic complications, diabetes, etc.), and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.
    • 本发明提供由以下通式表示的吡唑衍生物:其中R1表示H,任选取代的C 1-6烷基等; Q和T中的一个表示选自以下基团的基团:另一个表示 - (CH 2)n -Ar,其中Ar表示任选取代的C 6-10芳基或任选取代的C 1-8杂芳基; n表示0〜2的整数,可以具有取代基的C 1-6烷氧基,可以具有取代基的氨基,可以具有取代基的C2-9杂环烷基或任意取代的杂环稠合苯基; R表示任选取代的C 3-8环烷基,任选取代的C 6-10芳基等,其药学上可接受的盐或其前体药物,其在人1,5-脱水葡萄糖醇/果糖/甘露糖转运蛋白中表现出优异的抑制活性, 可用作预防,抑制与选自葡萄糖,果糖和甘露糖中的至少一种碳水化合物或与高血糖相关疾病(例如,糖尿病并发症,糖尿病等)的过量摄取相关疾病进展或治疗的药剂。 ),以及包含该药物组合物的药物组合物,其药学用途及其生产用中间体。
    • 25. 发明申请
    • FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF
    • 熔化的杂环衍生物,含有它们的药物组合物及其药物用途
    • US20090325900A1
    • 2009-12-31
    • US12089674
    • 2006-10-17
    • Kohsuke OhnoTakashi MiyagiTomonaga OzawaNobuhiko Fushimi
    • Kohsuke OhnoTakashi MiyagiTomonaga OzawaNobuhiko Fushimi
    • A61K31/695C07D215/58C07D211/72C07D311/02A61K31/47A61K31/44C07D223/16A61K31/55A61P5/24
    • C07D495/04
    • The present invention provides a compound useful as an agent for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides a fused heterocyclic derivative represented by the following general formula (I), a pharmaceutical composition containing the same, a medicinal use thereof and the like. In the formula (I), ring A represents 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; RA represents halogen, alkyl, alkenyl, alkynyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like; ring B represents aryl or heteroaryl; RB represents halogen, alkyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl or the like; E1 and E2 represent an oxygen atom or the like; U represents a single bond or alkylene; X represents a group represented by Y, —SO2—Y, —O— (alkylene)-Y, —O-Z in which Y represents Z, amino or the like; Z represents cycloalkyl, heterocycloalkyl, aryl, heteroaryl or the like; or the like.
    • 本发明提供了可用作预防或治疗性激素依赖性疾病等的药剂的化合物。 也就是说,本发明提供由以下通式(I)表示的稠合杂环衍生物,含有该杂环衍生物的药物组合物,其医药用途等。 在式(I)中,环A表示5元环状不饱和烃或5元杂芳基; 烷基,烯基,炔基,羧基,烷氧基,氨基甲酰基,烷基氨基甲酰基等; 环B表示芳基或杂芳基; RB代表卤素,烷基,羧基,烷氧基,氨基甲酰基,烷基氨基甲酰基等; E1和E2表示氧原子等; U表示单键或亚烷基; X表示Y表示的基团,-SO 2 -Y,-O-(亚烷基)-Y,-O-Z,Y表示Z,氨基等; Z表示环烷基,杂环烷基,芳基,杂芳基等; 或类似物。
    • 26. 发明申请
    • PHARMACEUTICAL FOR USE IN THE TREATMENT OF URETEROLITHIASIS
    • 用于治疗尿毒症的药物
    • US20090163571A1
    • 2009-06-25
    • US12093230
    • 2006-11-22
    • Mamoru KobayashiYoshitaka TomiyamaKumi Kobayashi
    • Mamoru KobayashiYoshitaka TomiyamaKumi Kobayashi
    • A61K31/404A61P13/00
    • C07D209/08A61K31/4045
    • The present invention provides pharmaceutical compositions useful for relieving pain caused by ureteral calculi, facilitating exclusion of ureteral calculi or the like. That is, the present invention provides a pharmaceutical composition for the treatment of ureteral lithiasis, which comprises as an active ingredient an indoline derivative represented by the following general formula (I) or a salt thereof. In the formula, R represents saturated or unsaturated aliphatic acyl which may have a substituent; hydroxyalkyl; aliphatic acyloxyalkyl; lower alkyl which has as a substituent lower alkoxy, carboxy, lower alkoxycarbonyl, aryl-substituted lower alkoxycarbonyl, carbamoyl, mono or di(lower alkyl)-substituted carbamoyl or cyano; optionally substituted aromatic acyl; furoyl or pyridylcarbonyl; R1 represents cyano or carbamoyl; and R2 represents lower alkyl which may have as a substituent halogen, cyano or aryl.
    • 本发明提供了用于缓解由输尿管结石引起的疼痛,有助于排除输尿管结石等的药物组合物。 也就是说,本发明提供了用于治疗输尿管结石的药物组合物,其包含作为活性成分的由以下通式(I)表示的二氢吲哚衍生物或其盐。 在该式中,R表示可具有取代基的饱和或不饱和脂肪族酰基; 羟烷基; 脂肪酰氧基烷基; 羧基,低级烷氧基羰基,芳基取代的低级烷氧基羰基,氨基甲酰基,一或二(低级烷基)取代的氨基甲酰基或氰基的低级烷基; 任选取代的芳族酰基; 糠酰基或吡啶基羰基; R1表示氰基或氨基甲酰基; 并且R 2表示可以具有卤素,氰基或芳基的取代基的低级烷基。
    • 27. 发明申请
    • Asymmetric Reduction Method
    • 不对称还原法
    • US20090043110A1
    • 2009-02-12
    • US12087092
    • 2006-12-26
    • Yoshinori MatsumotoYuki TakeuchiHiroyuki Yamamoto
    • Yoshinori MatsumotoYuki TakeuchiHiroyuki Yamamoto
    • C07D209/44
    • C07B53/00C07D209/44
    • The present invention is to provide a novel method for producing (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid which is useful as a therapeutic agent for diabetes. The present invention relates to a method for producing (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid, which is characterized in that 2-benzylidene-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid is subjected to a catalytic reduction reaction in the presence of an asymmetric catalyst prepared from a pyrrolidinebisphosphine compound (I) represented by the following general formula (I): wherein, R1 represents a linear or branched alkyl group having 1-10 carbon atoms, cycloalkyl group, aralkyl group or aryl group which may respectively have a substituent; and R2 and R3 independently represent an optionally substituted aryl group. The * mark in the pyrrolidine ring shows that the carbon atom at that position has the S configuration, and a rhodium compound.
    • 本发明提供可用作糖尿病治疗剂的(2S)-2-苄基-3-(顺式 - 六氢-2-异吲哚基羰基)丙酸的新方法。 本发明涉及(2S)-2-苄基-3-(顺 - 六氢-2-异二氢吲哚基羰基)丙酸的制备方法,其特征在于2-亚苄基-3-(顺式 - 六氢-2-异吲哚基羰基) )丙酸在由以下通式(I)表示的吡咯烷二膦化合物(I)制备的不对称催化剂存在下进行催化还原反应:其中,R1表示具有1-10个碳原子的直链或支链烷基 原子,环烷基,芳烷基或可分别具有取代基的芳基; 并且R 2和R 3独立地表示任选取代的芳基。 吡咯烷环中的*标记表示该位置的碳原子具有S构型和铑化合物。
    • 28. 发明授权
    • Glucopyranosyloxypyrazole derivatives and use thereof in medicines
    • 吡喃葡萄糖氧吡唑衍生物及其在药物中的应用
    • US07465713B2
    • 2008-12-16
    • US11247216
    • 2005-10-12
    • Hideki FujikuraNobuhiko FushimiToshihiro NishimuraTakeshi NakabayashiMasayuki Isaji
    • Hideki FujikuraNobuhiko FushimiToshihiro NishimuraTakeshi NakabayashiMasayuki Isaji
    • A01N43/04A61K31/70
    • A61K45/06A61K31/7056C07H17/02A61K2300/00
    • The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents a group represented by the general formula: (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
    • 本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物:其中R表示氢原子,低级烷基或形成前药的基团; Q和T之一表示由通式表示的基团:(其中P表示氢原子或形成前药的基团),而另一个表示低级烷基或卤代(低级烷基)基团; R2表示氢原子,低级烷基,低级烷氧基,低级烷硫基,卤代(低级烷基)或卤素原子; 并且条件是当R表示氢原子或低级烷基时,P不表示氢原子,或其药学上可接受的盐,其在人SGLT2中具有抑制活性并具有改善的口服吸收,因此可用作 用于预防或治疗与高血糖相关的疾病如糖尿病,糖尿病并发症或肥胖症的药剂及其药学上可接受的盐及其药学用途。
    • 29. 发明授权
    • Agent for treating interstitial cystitis
    • 间质性膀胱炎的治疗剂
    • US07446128B2
    • 2008-11-04
    • US11267299
    • 2005-11-07
    • Kouichi KaidohSatoshi Akahane
    • Kouichi KaidohSatoshi Akahane
    • A61N31/24C07C229/00
    • A61K31/24
    • A compound which can be used as an agent for treating interstitial cystitis. An agent for treating interstitial cystitis, which comprises a phenoxyacetic acid derivative represented by a general formula (I) wherein R1 represents hydroxyl group or a lower alkoxy group, or a pharmacologically acceptable salt thereof. Since the phenoxyacetic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof or a hydrate or solvate thereof has a selective β3-adrenoceptor stimulating activity and a remarkable action to inhibit a capsaicin-sensitive sensory nerve, it can be used as a preventive or therapeutic agent for interstitial cystitis and hyperactive bladder which are accompanied by pain, other diseases in which the capsaicin-sensitive sensory nerve is concerned (e.g., acute or chronic and systemic or topical pain and inflammation) and irritable bowel syndrome (IBS) and the like.
    • 可用作治疗间质性膀胱炎的药剂的化合物。 一种治疗间质性膀胱炎的药剂,其包含由通式(I)表示的苯氧基乙酸衍生物,其中R 1表示羟基或低级烷氧基,或其药理学上可接受的盐。 由于由通式(I)表示的苯氧基乙酸衍生物或其药学上可接受的盐或其水合物或溶剂合物具有选择性β3 - 肾上腺素能受体刺激活性和抑制辣椒素 - 敏感的感觉神经,它可以用作间质性膀胱炎和活动性膀胱的预防或治疗剂,其伴随着疼痛,其中涉及辣椒素敏感性感觉神经的其它疾病(例如,急性或慢性和全身或局部疼痛和 炎症)和肠易激综合征(IBS)等。